He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape based on this data. Plus, commentary on CMC, business development, oral therapies, and more.
View all episodes
By BiotechTV
4.3
66 ratings
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive landscape based on this data. Plus, commentary on CMC, business development, oral therapies, and more.
3,223 Listeners
1,902 Listeners
123 Listeners
324 Listeners
61 Listeners
9,899 Listeners
86 Listeners
34 Listeners
353 Listeners
19 Listeners
60 Listeners
514 Listeners
41 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners
46 Listeners